__NUXT_JSONP__("/way-forward", (function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w){return {data:[{article:{slug:m,title:"Methods of Research",toc:[{id:n,depth:o,text:p},{id:q,depth:o,text:r}],body:{type:"root",children:[{type:c,tag:"h1",props:{id:m},children:[{type:c,tag:f,props:{ariaHidden:g,href:"#way-forward",tabIndex:h},children:[{type:c,tag:i,props:{className:[j,k]},children:[]}]},{type:a,value:"Way Forward"}]},{type:a,value:b},{type:c,tag:d,props:{},children:[{type:c,tag:s,props:{alt:t,src:"https:\u002F\u002Fimages.unsplash.com\u002Fphoto-1518527989017-5baca7a58d3c?ixid=MnwxMjA3fDB8MHxwaG90by1wYWdlfHx8fGVufDB8fHx8&ixlib=rb-1.2.1&auto=format&fit=crop&w=1548&q=80"},children:[]}]},{type:a,value:b},{type:c,tag:u,props:{id:n},children:[{type:c,tag:f,props:{ariaHidden:g,href:"#analysis",tabIndex:h},children:[{type:c,tag:i,props:{className:[j,k]},children:[]}]},{type:a,value:p}]},{type:a,value:b},{type:c,tag:v,props:{},children:[]},{type:a,value:b},{type:c,tag:d,props:{},children:[{type:a,value:"The following are the limitations we could identify from the policies governing handling of biological samples in the Indian region (refer to Table of Policies for the policies we have studied). "}]},{type:a,value:b},{type:c,tag:l,props:{},children:[{type:a,value:b},{type:c,tag:e,props:{},children:[{type:a,value:b},{type:c,tag:d,props:{},children:[{type:a,value:"Based on the Guidelines of Transfer of Biological Material Policy in 1997, and the update to it in 2016, all human samples can be freely imported\u002Fexported\u002Ftransferred within the country, as long as the institutes\u002Fagencies submit a document with the details of the samples along with a declaration saying they would follow WHO\u002FDGFT guidelines, for commercial purposes. However, the agencies that could make use of this update include research laboratories and institutes. Hence, there seems to be a conflict regarding to whom the updated notification applies to. "}]},{type:a,value:b}]},{type:a,value:b},{type:c,tag:e,props:{},children:[{type:a,value:b},{type:c,tag:d,props:{},children:[{type:a,value:"In addition, although India was able to codify policies\u002Fguidelines for biotechnology and genetic engineering\u002Ftechnology way back in the 1990s, the policy language is vaguely defined towards distinct shipment protocols to be followed for each kind of biological sample. More focus has been shed on the biosafety and biocontainment aspects and not for sharing and shipping of such samples across and outside the Indian region. It was only after the onset of the pandemic, India realized this lacuna and established biorepositories and a sound sharing mechanism along with mention of SoPs for movement of SARS-CoV-2 related samples. We anticipate and believe that this model could be extended to other biological samples by amending the 1989 Act and 1997 Rules, thus expanding their purview.  "}]},{type:a,value:b}]},{type:a,value:b},{type:c,tag:e,props:{},children:[{type:a,value:b},{type:c,tag:d,props:{},children:[{type:a,value:"India's role as a member of the Australia Group in 2018 implies that it is liable to follow the guidelines as specified by the Guidelines for Transfers of Sensitive Chemical and Biological Items, 2015. However, in the Indian policies, no mention has been made with regards to this, and the policies such as the 1989 Act and 1997 rules have not been updated to demarcate the biological materials that fall under the category of controlled dual use items. Not doing so might lead to a lapse in following defined precautionary measures to prevent bioweapons proliferation."}]},{type:a,value:b}]},{type:a,value:b}]},{type:a,value:b},{type:c,tag:d,props:{},children:[{type:a,value:"Considering synthetic biology, India is yet to formally come up with its national strategy on it --- both policy and regulatory. Regulatory bodies are yet to form India's policy and regulatory framework focusing on defining what constitutes the science of synthetic biology; what kinds of research and development priorities will be made for the public sector; what will be the guidance for the private sector in synthetic biology research in the future that considers all relevant policy frameworks. This is directly reflected in the shipping policies of samples associated with synthetic biology work."}]},{type:a,value:b},{type:c,tag:d,props:{},children:[{type:a,value:"The Act passed in 1989 touches upon the following areas biotechnology, cell hybridization, gene technology, genetic engineering and microorganisms. There is a lacunae for constructive shipping policies tailored to the needs of synthetic biology work since there is a fundamental lack of understanding as to what synthetic biology constitutes. This translates to stakeholders having to navigate different policy frameworks since, in some cases, the application of their samples do not fall into the purview of any shipping policy. This is true both at the national and global front, based on our research in the USA, Germany and Australia."}]},{type:a,value:b},{type:c,tag:u,props:{id:q},children:[{type:c,tag:f,props:{ariaHidden:g,href:"#proposal",tabIndex:h},children:[{type:c,tag:i,props:{className:[j,k]},children:[]}]},{type:a,value:r}]},{type:a,value:b},{type:c,tag:v,props:{},children:[]},{type:a,value:b},{type:c,tag:d,props:{},children:[{type:a,value:"Our proposal involves using the supply chain model of vaccine distribution as a precedent for policy changes. The way forward is to include shared facilities that serve multiple stakeholders together."}]},{type:a,value:b},{type:c,tag:d,props:{},children:[{type:a,value:"At a policy level this would include "}]},{type:a,value:b},{type:c,tag:l,props:{},children:[{type:a,value:b},{type:c,tag:e,props:{},children:[{type:a,value:b},{type:c,tag:d,props:{},children:[{type:a,value:"-Making provisions and identifying overlaps in policy specific to samples for synthetic biology work in both the private and public sectors."}]},{type:a,value:b}]},{type:a,value:b},{type:c,tag:e,props:{},children:[{type:a,value:b},{type:c,tag:d,props:{},children:[{type:a,value:"-Recognising and including the end user in the policy framework as stakeholder for synthetic biology samples\u002Fwork."}]},{type:a,value:b}]},{type:a,value:b}]},{type:a,value:b},{type:c,tag:d,props:{},children:[{type:a,value:"At an implementation level this would include - "}]},{type:a,value:b},{type:c,tag:l,props:{},children:[{type:a,value:b},{type:c,tag:e,props:{},children:[{type:a,value:b},{type:c,tag:d,props:{},children:[{type:a,value:"-Biorepository capacity building across the nation to include synthetic biology samples, as extension of the biorepositories created for the pandemic purpose (Office Memorandum, DBT, dated 07.06.2021 titled the \"Standard Operating Procedures for exchange of infectious biosamples\u002Fbiospecimens from biorepository\")"}]},{type:a,value:b}]},{type:a,value:b},{type:c,tag:e,props:{},children:[{type:a,value:b},{type:c,tag:d,props:{},children:[{type:a,value:"-Establishment of Biofoundries - places for distributed manufacturing of biological parts to accelerate, automate and streamline research and innovation. Streamlining and building of pipelines has a direct effect on policy frameworks since regulatory bodies would have to accomodate efficient shipping protocols based on use cases of biological parts. This would eventually lead to consolidation of shipping of biological parts within the country in a regulated manner and recognition of synthetic biology within the policy framework "}]},{type:a,value:b}]},{type:a,value:b},{type:c,tag:e,props:{},children:[{type:a,value:b},{type:c,tag:d,props:{},children:[{type:a,value:"-Integration of biorepositories and biofoundries with national and international regulations "}]},{type:a,value:b}]},{type:a,value:b}]},{type:a,value:b},{type:c,tag:d,props:{},children:[{type:c,tag:s,props:{alt:t,src:"https:\u002F\u002Flh6.googleusercontent.com\u002FkQRz7EYf01l_tjhmDAsCCwnfaakNoEI0IN4Xk_rBpoA9e6vz-d7a4QOXlxy9p296XLdh-ZDqA_527v6mMsQJpKUzWPX7vJwS_JTQN6uC0qc09Ch8p3qjNXDmjKxo_h0COvJf7_Cg=s0"},children:[]}]},{type:a,value:b},{type:c,tag:d,props:{},children:[{type:a,value:"Fig 2. A threefold implementation solution to ease shipping of synthetic biology components in India"}]}]},dir:"\u002F",path:"\u002Fway-forward",extension:".md",createdAt:w,updatedAt:w}}],fetch:{},mutations:void 0}}("text","\n","element","p","li","a","true",-1,"span","icon","icon-link","ul","way-forward","analysis",2,"Analysis","proposal","Proposal ","img","","h2","hr","2021-09-26T10:15:06.951Z")));